Opinion|Videos|January 14, 2025
Future Considerations for Front-line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma
Panelists discuss how the future treatment landscape for transplant-ineligible/deferred NDMM is evolving toward more personalized approaches with quadruplet regimens, while acknowledging remaining challenges in optimizing duration of therapy, managing toxicities, and improving access to novel combinations.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly comment on where you see the treatment paradigm for TIE or deferred NDMM heading?
- What unmet needs still exist?
- Can you offer any clinical pearls?
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA received a BLA for etentamig in relapsed/refractory multiple myeloma, based on response and PFS gains in the phase 3 CERVINO trial.
Elranatamab improved PFS vs 3 standard regimens in relapsed/refractory multiple myeloma in the phase 3 MagnetisMM-32 trial.
The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.
Advertisement
Advertisement
Trending on OncLive
1
RELATIVITY-1093 Trial Aims to Advance Nivolumab Plus Relatlimab and Chemo in Nonsquamous NSCLC
2
Dostarlimab Monotherapy Elicits Durable cCRs in dMMR/MSI-H Locally Advanced Rectal Cancer
3
NEXERA-303 Trial Aims to Bring TGFβR2×PD-1 Bispecific Antibody INCA33890 Into First-Line MSS CRC
4
The OncFive: Top Oncology Articles for the Week of 10/25
5